By Colin Kellaher
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.
Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies.
Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug.
Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer.
Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer.
Shares of Summit were recently up 7.3% at $23.73 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 24, 2025 06:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。